Home  /  Resource Library  /  Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkins lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkins lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method

Study examined brentuximab vedotin combined with chemotherapy for treatment of Hodgkin lymphoma.